Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study.
Bruno VincenziAndrea NapolitanoMarta FioccoOlivier MirPiotr RutkowskiJean Yves BlayPeter ReichardtHeikki JoensuuElena FumagalliSpyridon GennatasNadia HindiMargherita NanniniMariella Spalato CerusoAntoine ItalianoGiovanni GrignaniAntonella BrunelloSilvia GasperoniTommaso Martino De PasGiuseppe BadalamentiMaria A PantaleoWinan J van HoudtNikki S IJzermanNeeltje SteeghsAndré B P van KuilenburgIngrid M E DesarJohanna FalkenhorstMarianna SillettaMarta SbaragliaGiuseppe ToniniJavier Martín-BrotoPeter HohenbergerAxel Le CesneRobin L JonesAngelo Paolo Dei TosAlessandro GronchiSebastian BauerPaolo G CasaliPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
In this retrospective series of patients with KIT exon 9-mutated GIST treated with adjuvant imatinib, a daily dose of 800 mg versus 400 mg did not show better results in terms of survival outcomes. Prospective evaluation of the more appropriate adjuvant treatment in this setting is warranted.